INVESTOR ALERT: Class Action Lawsuit on Behalf of Investors in Keryx Biopharmaceuticals Announced by Holzer & Holzer

ATLANTA--()--A class action lawsuit has been filed on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQ: KERX) securities between February 25, 2016 and August 1, 2016. The deadline to move for appointment as lead plaintiff in the case is October 3, 2016.

The lawsuit, which is pending in the United States District Court for the Southern District of New York, alleges, among other things, that Keryx failed to adequately disclose that the Company was experiencing production-related difficulties in converting an active pharmaceutical ingredient to a finished drug product at its contract manufacturer and further alleges that the issue resulted in decreased production yields of Auryxia.

If you purchased Keryx securities between those dates and suffered losses on that investment, you are encouraged to contact Marshall P. Dees, Esq. via email at mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832, to discuss your legal rights before the October 3, 2016 lead plaintiff deadline.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

Contacts

Holzer & Holzer, LLC
Marshall P. Dees, Esq., 888-508-6832 (toll-free)
mdees@holzerlaw.com

Release Summary

Class action filed against Keryx

Contacts

Holzer & Holzer, LLC
Marshall P. Dees, Esq., 888-508-6832 (toll-free)
mdees@holzerlaw.com